Cargando…

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

BACKGROUND: HLX02 is an approved biosimilar of trastuzumab. OBJECTIVE: This study aimed to evaluated the efficacy, safety, and immunogenicity of HLX02 compared with reference trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Binghe, Zhang, Qingyuan, Sun, Tao, Li, Wei, Teng, Yue’e, Hu, Xichun, Bondarenko, Igor, Adamchuk, Hryhoriy, Zhang, Liangming, Trukhin, Dmytro, Wang, Shusen, Zheng, Hong, Tong, Zhongsheng, Shparyk, Yaroslav, Wang, Qingyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084805/ https://www.ncbi.nlm.nih.gov/pubmed/33826080 http://dx.doi.org/10.1007/s40259-021-00475-w

Ejemplares similares

Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin(®) with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology
por: Xie, Liqi, et al.
Publicado: (2020)

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
por: Li, Rubi K., et al.
Publicado: (2022)

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
por: Xu, Binghe, et al.
Publicado: (2016)

HLX in AML: novel prognostic and therapeutic target
por: Pandolfi, Ashley, et al.
Publicado: (2012)

Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI
por: Liang, Jianye, et al.
Publicado: (2022)

Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma
por: Nagel, Stefan, et al.
Publicado: (2018)

HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
por: Yang, Jingjing, et al.
Publicado: (2022)

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study
por: Qin, Shukui, et al.
Publicado: (2021)

TBX21 and HLX1 Polymorphisms Influence Cytokine Secretion at Birth
por: Casaca, Vera Isabel, et al.
Publicado: (2012)

The Hlx homeobox transcription factor is required early in enteric nervous system development
por: Bates, Michael D, et al.
Publicado: (2006)

Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL
por: Nagel, Stefan, et al.
Publicado: (2019)

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
por: Ma, Fei, et al.
Publicado: (2023)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

Rs868058 in the Homeobox Gene HLX Contributes to Early-Onset Fetal Growth Restriction
por: Wujcicka, Wioletta Izabela, et al.
Publicado: (2022)

Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study
por: Zeng, Xiaofeng, et al.
Publicado: (2022)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial
por: Blayney, Douglas W., et al.
Publicado: (2022)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020)

HLX affects cell cycle and proliferation in AML cells via the JAK/STAT signaling pathway
por: Zhu, Xia-Yin, et al.
Publicado: (2020)

Trastuzumab immunogenicity development in patients’ sera and in laboratory animals
por: Kilany, Lobna Abdel Aziz, et al.
Publicado: (2021)

Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma
por: Ren, Zhenggang, et al.
Publicado: (2022)

A metabolic interplay coordinated by HLX regulates myeloid differentiation and AML through partly overlapping pathways
por: Piragyte, Indre, et al.
Publicado: (2018)

Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
por: Xu, Yanpeng, et al.
Publicado: (2019)

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
por: Cai, Lin, et al.
Publicado: (2021)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
por: Zhang, Hong, et al.
Publicado: (2021)

A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers
por: Zhu, Xiaoxue, et al.
Publicado: (2021)

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial
por: Pivot, Xavier, et al.
Publicado: (2023)

Hepatocyte growth factor regulates HLX1 gene expression to modulate HTR-8/SVneo trophoblast cells
por: Liu, Hai-Ying, et al.
Publicado: (2012)

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
por: Trukhin, Dmytro, et al.
Publicado: (2021)

Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
por: Pimentel, Franklin Fernandes, et al.
Publicado: (2018)

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2021)

Study on the Mechanism of Platelet-Released Clusterins Inducing Restenosis after Carotid Endarterectomy by Activating TLR3/NF-κb p65 Signaling Pathway
por: Meng, Qingyu, et al.
Publicado: (2022)

Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial
por: Morita, Jun, et al.
Publicado: (2015)

Transcription factor Hlx controls a systematic switch from white to brown fat through Prdm16-mediated co-activation
por: Huang, Lei, et al.
Publicado: (2017)

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
por: Cao, Jun, et al.
Publicado: (2023)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL)
por: Nagel, Stefan, et al.
Publicado: (2020)

Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy
por: Issafras, Hassan, et al.
Publicado: (2021)

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
por: Toi, Masakazu, et al.
Publicado: (2017)

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
por: Wu, Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gqui00folsbf5j8fmnki15hdbe